Pantarhin Pharma Inc. is proud to announce advancements in our novel enzyme, BELACT®. This biotechnologically produced hyaluronidase offers a dual action, combining the functionalities of PH20 and HYAL4 within a single molecule. This unique approach represents a significant step forward in addressing the underlying causes of atherosclerosis.
BELACT®’s mechanism of action targets the very building blocks of atherosclerotic plaques, breaking down proteoglycans and hyaluronic acid. Crucially, this process preserves the integrity of blood vessels, allowing natural repair mechanisms to function effectively. Unlike therapies that simply stabilize or bypass deposits, BELACT® actively reduces them.
The benefits extend beyond plaque reduction. By breaking down pathological components of the extracellular matrix, BELACT® helps blood vessels regain their natural flexibility and elasticity. This restoration of vessel function addresses the root cause of the pathophysiology, offering a more comprehensive approach than existing symptomatic treatments.
Produced entirely through biotechnology, BELACT® boasts a sustainable and GMP compliant manufacturing process without animal components. Its high activity, demonstrated in standardized in vitro tests, combined with an expected good tolerability profile based on similarity to human enzymes, makes BELACT® a promising candidate for addressing atherosclerosis on a large scale.